Aquestive Therapeutics, Inc.
AQST
$6.51
-$0.18-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.13M | 54.23M | 57.56M | 58.90M | 58.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.13M | 54.23M | 57.56M | 58.90M | 58.36M |
| Cost of Revenue | 17.17M | 17.14M | 17.87M | 18.03M | 18.39M |
| Gross Profit | 26.96M | 37.09M | 39.69M | 40.87M | 39.97M |
| SG&A Expenses | 59.91M | 58.56M | 50.18M | 43.72M | 38.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.73M | 95.41M | 88.33M | 80.00M | 73.55M |
| Operating Income | -52.60M | -41.18M | -30.77M | -21.10M | -15.19M |
| Income Before Tax | -65.06M | -54.25M | -44.15M | -35.09M | -25.76M |
| Income Tax Expenses | -14.00K | -14.00K | -14.00K | 101.00K | -39.00K |
| Earnings from Continuing Operations | -65.04 | -54.24 | -44.14 | -35.19 | -25.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.04M | -54.24M | -44.14M | -35.19M | -25.72M |
| EBIT | -52.60M | -41.18M | -30.77M | -21.10M | -15.19M |
| EBITDA | -51.99M | -40.51M | -30.03M | -20.04M | -14.02M |
| EPS Basic | -0.69 | -0.58 | -0.52 | -0.45 | -0.36 |
| Normalized Basic EPS | -0.42 | -0.37 | -0.33 | -0.28 | -0.22 |
| EPS Diluted | -0.69 | -0.59 | -0.52 | -0.46 | -0.36 |
| Normalized Diluted EPS | -0.42 | -0.37 | -0.33 | -0.28 | -0.22 |
| Average Basic Shares Outstanding | 377.11M | 368.69M | 346.81M | 322.81M | 296.40M |
| Average Diluted Shares Outstanding | 377.11M | 368.69M | 346.81M | 322.81M | 296.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |